Source: Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Bence M. Nagy, Gabor Kovacs, Adrienn Tornyos, Eva Svehlikova, Vasile Foris, Chandran Nagaraj, Grazyna Kwapiszewska, Thomas R. Pieber, Andrea Olschewski, Horst Olschewski. No indication of insulin resistance in idiopathic pulmonary arterial hypertension with preserved physical activity. Eur Respir J, 55 (6) 1901228; 10.1183/13993003.01228-2019

Member's Comments

No comment yet.

Related content which might interest you: No indication of insulin resistance in idiopathic PAH with preserved physical activity Source: Virtual Congress 2020 – Experimental approaches to pulmonary hypertension Year: 2020 Impact of therapies on insulin resistance in pulmonary arterial hypertension Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010 Insulin resistance in pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 318-324 Year: 2009 The arterial load in pulmonary hypertension Source: Eur Respir Rev 2010 19: 197-203 Year: 2010 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 Pulmonary hypertension in children Source: Eur Respir Mon 2012; 57: 94-107 Year: 2012 Metabolic, cardiovascular and gas exchange abnormalities during activities of daily life in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Increased renin-angiotensin-aldosteron system activity in lungs of patients with idiopathic pulmonary arterial hypertension Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension Source: Eur Respir J 2009; 34: 770 Year: 2009 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Comparison of exercise capacity, pulmonary functions, respiratory and peripheral muscle strength between patients with idiopathic pulmonary arterial hypertension and Eisenmenger syndrome Source: Annual Congress 2012 - Assessment of physical activity, exercise, muscle function and clinical characteristics as outcomes in physiotherapy and rehabilitation Year: 2012 Impact on survival of pulmonary function abnormalities in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Functional impact of exercise pulmonary hypertension in patients with borderline pulmonary arterial pressure Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1514-1516 Year: 2016 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Predictors of physical activity in pulmonary arterial and chronic thromboembolic pulmonary hypertension Source: International Congress 2019 – Chronic thromboembolic pulmonary hypertension Year: 2019 Pulmonary vascular response to exercise in heart-failure patients with pulmonary hypertension: role of a pre-capillary component Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Differences in the activity of the angiotensin converting enzyme 2 axis in patients with idiopathic pulmonary arterial hypertension and congenital heart defect related pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target Source: Eur Respir J 2011; 38: 1453-1460 Year: 2011